Nkcfo LLC Purchases Shares of 275 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Nkcfo LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, HoldingsChannel reports. The firm bought 275 shares of the biotechnology company’s stock, valued at approximately $43,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 160.0% in the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after acquiring an additional 2,917,797 shares during the period. Farallon Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Norges Bank bought a new position in Sarepta Therapeutics in the fourth quarter worth $80,697,000. Bank of Nova Scotia acquired a new stake in Sarepta Therapeutics during the fourth quarter worth $50,990,000. Finally, Avoro Capital Advisors LLC increased its holdings in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Leerink Partners lifted their target price on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. UBS Group lifted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday. BMO Capital Markets boosted their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Finally, William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,801 shares of company stock valued at $8,399,586. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $127.21 on Friday. The firm’s 50 day simple moving average is $137.26 and its 200 day simple moving average is $132.60. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a market capitalization of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the business posted ($0.27) earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.